|Dr. Stelios Papadopoulos||Co-Founder & Chairman||N/A||N/A||1948|
|Dr. Michael M. Morrissey||CEO, Pres & Director||1.65M||1.2M||1961|
|Mr. Christopher J. Senner||Exec. VP, CFO & Principal Accounting Officer||844.62k||N/A||1968|
|Dr. Peter Lamb Ph.D.||Exec. VP of Scientific Strategy & Chief Scientific Officer||720.25k||1.35M||1961|
|Mr. Jeffrey J. Hessekiel J.D.||Exec. VP, Gen. Counsel & Sec.||760k||956k||1969|
Exelixis, Inc., a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. It also offers COTELLIC tablets, an inhibitor of MEK in combination with vemurafenib for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma in the United States; and in combination with vemurafenib in other territories, including the European Union, Switzerland, Canada, Australia, and Brazil. Exelixis, Inc. has collaboration and license agreements with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds and programs. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
Exelixis, Inc.’s ISS Governance QualityScore as of April 1, 2018 is 4. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 5; Compensation: 6.